Displaying 1 - 12 of 24

Display:

12 24 48

Viral Hepatitis

5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View

Viral Hepatitis

5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View

Viral Hepatitis

5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View

Viral Hepatitis

5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View

Immune-Mediated and Cholestatic Diseases

4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View

Immune-Mediated and Cholestatic Diseases

4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View

Immune-Mediated and Cholestatic Diseases

4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View

Viral Hepatitis

6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View

Viral Hepatitis

6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View

Viral Hepatitis

6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View

Viral Hepatitis

6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View

Viral Hepatitis

6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View

Displaying 1 - 12 of 24

Display:

12 24 48